A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Public ClinicalTrials.gov record NCT03412565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Study identification
- NCT ID
- NCT03412565
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 265 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- Carfilzomib Drug
- Daratumumab Drug
- Dexamethasone Drug
- Lenalidomide Drug
- Melphalan Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2018
- Primary completion
- Aug 11, 2020
- Completion
- Apr 17, 2024
- Last update posted
- Apr 28, 2025
2018 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Center of Central Connecticut - Southington | Southington | Connecticut | 06489-3237 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| UF Health Cancer Center at Orlando Health | Orlando | Florida | 32806 | — |
| Karmonos Cancer Institute | Detroit | Michigan | 48201 | — |
| Providence Cancer Center | Southfield | Michigan | 48075 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Nebraska Hematology and Oncology | Lincoln | Nebraska | 68506 | — |
| Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| NYU Winthrop | Mineola | New York | 11501 | — |
| Mt. Sinai School of Medicine | New York | New York | 10029 | — |
| Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | — |
| Avera Medical Group - Oncology & Hematology | Sioux Falls | South Dakota | 57105 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84121 | — |
| University of Virginia Cancer Center - Emily Couric Clinical Cancer Center - Women's Oncology Clinic | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03412565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03412565 live on ClinicalTrials.gov.